CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
6.10
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

OraSure Technologies Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 6.1
Open* 6.1
1-Year Change* 5.35%
Day's Range* 6.07 - 6.19
52 wk Range 4.38-8.45
Average Volume (10 days) 807.76K
Average Volume (3 months) 14.14M
Market Cap 592.28M
P/E Ratio 12.09
Shares Outstanding 73.48M
Revenue 452.67M
EPS 0.67
Dividend (Yield %) N/A
Beta 0.17
Next Earnings Date Feb 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 6.10 -0.04 -0.65% 6.14 6.19 6.06
Mar 27, 2024 6.10 0.04 0.66% 6.06 6.21 6.06
Mar 26, 2024 6.05 -0.13 -2.10% 6.18 6.32 6.05
Mar 25, 2024 6.18 -0.14 -2.22% 6.32 6.34 6.10
Mar 22, 2024 6.28 0.08 1.29% 6.20 6.33 6.19
Mar 21, 2024 6.31 -0.12 -1.87% 6.43 6.55 6.31
Mar 20, 2024 6.48 -0.18 -2.70% 6.66 6.66 6.40
Mar 19, 2024 6.69 -0.04 -0.59% 6.73 6.80 6.56
Mar 18, 2024 6.77 0.12 1.80% 6.65 6.92 6.62
Mar 15, 2024 6.63 -0.13 -1.92% 6.76 6.93 6.60
Mar 14, 2024 6.85 -0.13 -1.86% 6.98 7.10 6.85
Mar 13, 2024 6.99 0.04 0.58% 6.95 7.17 6.94
Mar 12, 2024 7.03 0.21 3.08% 6.82 7.09 6.82
Mar 11, 2024 6.87 -0.27 -3.78% 7.14 7.27 6.81
Mar 8, 2024 7.20 -0.15 -2.04% 7.35 7.40 7.09
Mar 7, 2024 7.25 0.30 4.32% 6.95 7.25 6.95
Mar 6, 2024 6.93 -0.03 -0.43% 6.96 6.97 6.81
Mar 5, 2024 6.96 0.14 2.05% 6.82 6.97 6.78
Mar 4, 2024 6.85 -0.40 -5.52% 7.25 7.26 6.80
Mar 1, 2024 7.24 0.04 0.56% 7.20 7.34 6.98

OraSure Events

Time (UTC) Country Event
Wednesday, May 8, 2024

Time (UTC)

20:05

Country

US

Event

Q1 2024 OraSure Technologies Inc Earnings Release
Q1 2024 OraSure Technologies Inc Earnings Release

Forecast

-

Previous

-
Wednesday, May 15, 2024

Time (UTC)

16:30

Country

US

Event

OraSure Technologies Inc Annual Shareholders Meeting
OraSure Technologies Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 387.479 233.674 171.721 154.605 181.743
Revenue 387.479 233.674 171.721 154.605 181.743
Cost of Revenue, Total 239.842 116.074 69.853 60.022 68.13
Gross Profit 147.637 117.6 101.868 94.583 113.613
Total Operating Expense 410.436 243.838 176.898 135.994 153.314
Selling/General/Admin. Expenses, Total 117.444 95.079 76.719 67.156 67.699
Research & Development 36.237 34.17 31.032 19.629 16.25
Unusual Expense (Income) 16.913 -1.485 0.393 -10.813 1.235
Operating Income -22.957 -10.164 -5.177 18.611 28.429
Other, Net 4.928 1.539 1.99 4.059 2.456
Net Income Before Taxes -16.476 -9.292 -3.524 21.331 31.716
Net Income After Taxes -17.934 -22.998 -14.922 16.656 2.672
Net Income Before Extra. Items -17.934 -22.998 -14.922 16.656 2.672
Net Income -17.934 -22.998 -14.922 16.656 20.396
Income Available to Common Excl. Extra. Items -17.934 -22.998 -14.922 16.656 2.672
Income Available to Common Incl. Extra. Items -17.934 -22.998 -14.922 16.656 20.396
Diluted Net Income -17.934 -22.998 -14.922 16.656 20.396
Diluted Weighted Average Shares 72.505 71.981 67.505 62.17 62.532
Diluted EPS Excluding Extraordinary Items -0.24735 -0.3195 -0.22105 0.26791 0.04273
Diluted Normalized EPS -0.09573 -0.33291 -0.21727 0.1321 0.05557
Dilution Adjustment
Interest Income (Expense), Net Non-Operating 1.553 -0.667 -0.337 -1.339 0.831
Total Extraordinary Items 17.724
Other Operating Expenses, Total -1.099
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 85.441 154.963 123.078 116.463 80.231
Revenue 85.441 154.963 123.078 116.463 80.231
Cost of Revenue, Total 51.836 89.113 73.489 70.271 52.434
Gross Profit 33.605 65.85 49.589 46.192 27.797
Total Operating Expense 91.87 130.642 109.643 115.588 101.702
Selling/General/Admin. Expenses, Total 24.663 27.819 27.307 29.001 29.263
Research & Development 7.661 9.994 8.999 9.757 9.463
Unusual Expense (Income) 7.745 3.74 -0.152 6.559 10.542
Operating Income -6.429 24.321 13.435 0.875 -21.471
Interest Income (Expense), Net Non-Operating -0.492 0.05 -0.843 2.342 0.783
Other, Net 1.959 2.623 2.804 0.913 0.93
Net Income Before Taxes -4.962 26.994 15.396 4.13 -19.758
Net Income After Taxes -4.796 27.219 15.562 5.273 -18.589
Net Income Before Extra. Items -4.796 27.219 15.562 5.273 -18.589
Net Income -4.796 27.219 15.562 5.273 -18.589
Income Available to Common Excl. Extra. Items -4.796 27.219 15.562 5.273 -18.589
Income Available to Common Incl. Extra. Items -4.796 27.219 15.562 5.273 -18.589
Diluted Net Income -4.796 27.219 15.562 5.273 -18.589
Diluted Weighted Average Shares 73.324 73.966 72.676 72.785 72.496
Diluted EPS Excluding Extraordinary Items -0.06541 0.36799 0.21413 0.07245 -0.25641
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.00325 0.40086 0.21277 0.13102 -0.16189
Other Operating Expenses, Total -0.035 -0.024 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 325.19 299.306 288.893 224.55 219.312
Cash and Short Term Investments 110.847 153.041 209.401 156.338 156.572
Cash & Equivalents 83.98 116.762 160.802 75.715 88.438
Short Term Investments 26.867 36.279 48.599 80.623 68.134
Total Receivables, Net 70.797 45.323 38.835 36.948 34.842
Accounts Receivable - Trade, Net 70.797 45.323 38.835 36.948 34.842
Total Inventory 95.704 53.138 31.863 23.155 22.888
Prepaid Expenses 6.273 7.939 3.86 2.433 1.925
Other Current Assets, Total 41.569 39.865 4.934 5.676 3.085
Total Assets 444.18 460.99 454.472 349.295 315.571
Property/Plant/Equipment, Total - Net 71.105 84.984 57.633 37.286 24.299
Property/Plant/Equipment, Total - Gross 140.986 146.141 111.237 84.168 67.096
Accumulated Depreciation, Total -69.881 -61.157 -53.604 -46.882 -42.797
Goodwill, Net 35.104 40.279 40.351 36.201 18.521
Intangibles, Net 11.694 14.343 17.904 14.674 5.137
Other Long Term Assets, Total 1.087 5.069 1.973 3.164 3.55
Total Current Liabilities 69.063 68.064 46.489 32.713 27.98
Accounts Payable 38.02 28.024 17.407 9.567 10.598
Accrued Expenses 27.526 35.959 23.352 15.32 12.414
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.338 3.142 5.213 7.213 4.968
Total Liabilities 79.755 80.457 55.901 42.15 32.193
Total Long Term Debt 0.503 1.952 0.895 1.372 0
Deferred Income Tax 0.408 2.234 1.195 0.899 0.901
Other Liabilities, Total 9.781 8.207 7.322 7.166 3.312
Total Equity 364.425 380.533 398.571 307.145 283.378
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.00007 0.00007 0.00007 0.00006 0
Additional Paid-In Capital 520.446 511.063 505.123 401.814 401.273
Retained Earnings (Accumulated Deficit) -137.586 -120.453 -97.455 -82.533 -99.189
Other Equity, Total -18.2151 -9.64307 -8.74907 -12.1361 -18.706
Total Liabilities & Shareholders’ Equity 444.18 460.99 454.472 349.295 315.571
Total Common Shares Outstanding 72.734 72.734 71.738 61.731 61.276
Long Term Investments 17.009 47.718 33.42 44.752
Current Port. of LT Debt/Capital Leases 1.179 0.939 0.517 0.613
Capital Lease Obligations 0.503 1.952 0.895 1.372
Unrealized Gain (Loss) -0.22 -0.434 -0.348
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 356.464 341.567 343.595 325.19 279.732
Cash and Short Term Investments 224.891 185.936 112.372 110.847 101.637
Cash & Equivalents 217.533 185.936 90.194 83.98 75.205
Short Term Investments 7.358 0 22.178 26.867 26.432
Total Receivables, Net 53.402 52.75 107.445 70.797 61.306
Accounts Receivable - Trade, Net 53.402 52.75 107.445 70.797 61.306
Total Inventory 59.264 73.284 77.189 95.704 78.805
Prepaid Expenses 6.423 5.248 6.161 6.273 5.844
Other Current Assets, Total 12.484 24.349 40.428 41.569 32.14
Total Assets 458.432 453.594 459.415 444.18 432.208
Property/Plant/Equipment, Total - Net 62.122 63.528 68.401 71.105 102.543
Property/Plant/Equipment, Total - Gross 146.29 147.951 140.801 129.294 153.81
Accumulated Depreciation, Total -84.168 -84.423 -72.4 -69.881 -68.626
Goodwill, Net 35.033 35.606 35.204 35.104 34.476
Intangibles, Net 3.793 10.665 11.184 11.694 11.919
Long Term Investments 0
Other Long Term Assets, Total 1.02 2.228 1.031 1.087 3.538
Total Current Liabilities 40.947 46.42 55.123 69.063 71.697
Accounts Payable 14.966 17.753 27.396 38.02 40.37
Accrued Expenses 23.157 25.706 24.434 27.526 27.35
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1 1.08 1.229 1.179 1.242
Other Current Liabilities, Total 1.824 1.881 2.064 2.338 2.735
Total Liabilities 53.547 59.455 65.236 79.755 90.318
Total Long Term Debt 0.247 0.436 0.472 0.503 0.935
Capital Lease Obligations 0.247 0.436 0.472 0.503 0.935
Deferred Income Tax 0 0 0.409 0.408 2.551
Other Liabilities, Total 12.353 12.599 9.232 9.781 15.135
Total Equity 404.885 394.139 394.179 364.425 341.89
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.00007 0.00007 0.00007 0.00007 0.00007
Additional Paid-In Capital 526.261 523.861 521.964 520.446 518.17
Retained Earnings (Accumulated Deficit) -104.004 -115.163 -110.367 -137.586 -153.949
Unrealized Gain (Loss) 0 0 0 -0.22 -0.267
Other Equity, Total -17.3721 -14.5591 -17.4181 -18.2151 -22.0641
Total Liabilities & Shareholders’ Equity 458.432 453.594 459.415 444.18 432.208
Total Common Shares Outstanding 73.483 73.413 73.254 72.734 72.619
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -17.934 -22.998 -14.922 16.656 20.396
Cash From Operating Activities -47.202 -35.382 5.807 9.804 39.09
Cash From Operating Activities 15.308 11.658 9.387 7.339 6.451
Deferred Taxes -1.651 1.026 -0.392 -1.457 -0.919
Non-Cash Items 27.639 13.367 7.042 -3.549 15.608
Cash Taxes Paid 9.446 13.727 9.263 10.611 17.126
Changes in Working Capital -70.564 -38.435 4.692 -9.185 -2.446
Cash From Investing Activities 21.085 -5.501 -14.029 -19.797 -17.427
Capital Expenditures -63.909 -48.117 -28.924 -9.314 -6.344
Other Investing Cash Flow Items, Total 84.994 42.616 14.895 -10.483 -11.083
Cash From Financing Activities -3.828 -2.817 92.479 -4.682 -1.891
Financing Cash Flow Items -0.208 -0.264 -3.004
Issuance (Retirement) of Stock, Net -2.239 -1.867 96.17 -3.516 -1.891
Foreign Exchange Effects -2.837 -0.34 0.83 1.952 -4.203
Net Change in Cash -32.782 -44.04 85.087 -12.723 15.569
Issuance (Retirement) of Debt, Net -1.381 -0.686 -0.687 -1.166
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 27.219 -17.934 -33.496 -38.769 -19.967
Cash From Operating Activities 6.002 -47.202 -29.19 -45.489 -35.821
Cash From Operating Activities 3.696 15.308 11.391 7.464 3.682
Deferred Taxes 0 -1.651 0.542 0.361 0.2
Non-Cash Items 3.709 27.639 28.934 20.171 5.918
Cash Taxes Paid -0.01 9.446 9.4 9.107 3.57
Changes in Working Capital -28.622 -70.564 -36.561 -34.716 -25.654
Cash From Investing Activities 1.016 21.085 -4.488 -2.264 -9.939
Capital Expenditures -3.958 -63.909 -66.786 -59.243 -48.407
Other Investing Cash Flow Items, Total 4.974 84.994 62.298 56.979 38.468
Cash From Financing Activities -1.331 -3.828 -3.027 -2.539 -1.395
Financing Cash Flow Items -0.046 -0.208 -0.208 -0.208 -0.208
Issuance (Retirement) of Stock, Net -1.137 -2.239 -1.993 -1.939 -1.034
Issuance (Retirement) of Debt, Net -0.148 -1.381 -0.826 -0.392 -0.153
Foreign Exchange Effects 0.527 -2.837 -4.852 -0.311 1.114
Net Change in Cash 6.214 -32.782 -41.557 -50.603 -46.041

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

OraSure Company profile

About OraSure Technologies, Inc.

OraSure Technologies, Inc. (OraSure) is a medical device company that develops, manufactures, and markets medical devices and diagnostic products. The Company's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, OraSure Technologies, Inc. revenues increased 36% to $233.7M. Net loss increased 54% to $23M. Revenues reflect Molecular Solutions segment increase of 35% to $143.6M, Diagnostics segment increase of 38% to $90M, United States segment increase of 44% to $188.4M, Other Regions segment increase of 9% to $31.5M, Europe segment increase of 14% to $13.8M.

Equity composition

Common Stock $.000001 Par, 03/11, 120M auth., 46,626,324 o/s. Insiders own 2.05%. 9/29/00, Company formed through pooling between Epitope and OraSure Technologies.

Industry: Medical Equipment, Supplies & Distribution (NEC)

220 E First St
BETHLEHEM
PENNSYLVANIA 18015
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,556.84 Price
-0.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

70,610.80 Price
-0.700% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.64 Price
-0.020% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading